Current methods for the reduction of blood-borne pathogens: a comprehensive literature review.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Blood transfusion = Trasfusione del sangue

• Publication date

  2013-03-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.2450/2013.0218-12PMID 23522896PMCID PMC3729123
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathogen reduction technologies

  2014cited by this paper
• Two pathogen reduction technologies—methylene blue plus light and shortwave ultraviolet light—effectively inactivate hepatitis C virus in blood products

  2013cited by this paper
• [Seventeen years of haemovigilance in France: assessment and outlook].

  2011cited by this paper
• Stored red blood cell viability is maintained after treatment with a second‐generation S‐303 pathogen inactivation process

  2011cited by this paper
• Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates

  2011cited by this paper
• Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3‐year period

  2011cited by this paper
• Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction

  2011cited by this paper
• Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation

  2011cited by this paper
• Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light

  2011cited by this paper
• UVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma

  2011cited by this paper
• A comparison of methods of pathogen inactivation of FFP

  2011cited by this paper
• Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood SystemTM

  2011cited by this paper
• Dose of prophylactic platelet transfusions and prevention of hemorrhage.

  2010cited by this paper
• Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction

  2010cited by this paper
• An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment

  2010cited by this paper
• Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC.

  2010cited by this paper
• The status of pathogen-reduced plasma.

  2010cited by this paper
• A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

  2010cited by this paper
• The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.

  2010cited by this paper
• BLOOD COMPONENTS: A novel approach to pathogen reduction in platelet concentrates using short‐wave ultraviolet light

  2009cited by this paper
• Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies

  2009cited by this paper
• Platelet function assessed by shear‐induced deposition of split triple‐dose apheresis concentrates treated with pathogen reduction technologies

  2009cited by this paper
• Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.

  2009cited by this paper
• Properties of pathogen-inactivated plasma components.

  2009cited by this paper
• A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns

  2009cited by this paper
• Functional characteristics of apheresis‐derived platelets treated with ultraviolet light combined with either amotosalen‐HCl (S‐59) or riboflavin (vitamin B2) for pathogen‐reduction

  2009cited by this paper
• A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment

  2008cited by this paper
• UV-C irradiation disrupts platelet surface disulfide bonds and activates the platelet integrin alphaIIbbeta3.

  2008cited by this paper
• Methylene blue‐photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study

  2008cited by this paper
• ADAMTS‐13 activity and von Willebrand factor levels in methylene blue photo‐inactivated plasma processed by either the Springe method or an ‘in house’ system

  2008cited by this paper
• An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment

  2008cited by this paper
• Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus

  2008cited by this paper
• Pathogen inactivation: making decisions about new technologies

  2007cited by this paper
• Leukoreduced buffy coat–derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions

  2007cited by this paper
• Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood–derived platelets and apheresis platelets

  2007cited by this paper
• Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease.

  2006cited by this paper
• Bacterial contamination of platelet concentrates prepared by different methods: results of standardized sterility testing in Germany

  2006cited by this paper
• Therapeutic efficacy and safety of red blood cells treated with a chemical process (S‐303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients

  2005cited by this paper
• Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set

  2005cited by this paper
• Pathogen Inactivation of Cellular Blood Products – Still Plenty of Reason to Be Careful

  2005cited by this paper
• Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction

  2005cited by this paper
• Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.

  2004cited by this paper
• Inactivation of mycoplasma species in blood by INACTINE PEN110 process

  2004cited by this paper
• Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light

  2004cited by this paper
• Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease

  2004cited by this paper
• Functional characteristics of buffy‐coat PLTs photochemically treated with amotosalen‐HCl for pathogen inactivation

  2004cited by this paper
• Evaluation of processing characteristics of photochemically treated pooled platelets: target requirements for the INTERCEPT Blood System comply with routine use after process optimization

  2004cited by this paper
• Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.

  2003cited by this paper
• Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States

  2003cited by this paper
• Status of NAT screening for HCV, HIV and HBV--experiences of the German Red Cross Blood Donation Services.

  2002cited by this paper
• Incidence and significance of the bacterial contamination of blood components.

  2002cited by this paper
• Determinants of transfusion‐associated bacterial contamination: results of the French Bacthem Case‐Control Study

  2001cited by this paper
• Labile Blood Components and Blood Donation

  2001cited by this paper
• Single‐donor platelets reduce the risk of septic platelet transfusion reactions

  2001cited by this paper
• Photochemical Inactivation of Bacteria and HIV in Buffy‐Coat‐Derived Platelet Concentrates under Conditions That Preserve in vitro Platelet Function

  2000cited by this paper
• Febrile and allergic transfusion reactions after the transfusion of white cell‐poor platelet preparations

  1999cited by this paper
• Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light

  1999cited by this paper
• Virus Inactivation of Blood Products by Phenothiazine Dyes and Light

  1997cited by this paper
• The role of the plasma from platelet concentrates in transfusion reactions.

  1994cited by this paper
• Regulation of Carbohydrate Metabolism in Platelets

  1978cited by this paper

• Platelet Transfusion for Patients with Cancer: An Update

  2025cites this paper
• Rapid Sterilization of Clinical Apheresis Blood Products Using Ultra-High Dose Rate Radiation

  2025cites this paper
• Viral agents (2nd section)

  2024cites this paper
• Advancements in Immunology and Microbiology Research: A Comprehensive Exploration of Key Areas

  2024cites this paper
• Evaluation of bacterial safety approaches of platelet blood concentrates: bacterial screening and pathogen reduction

  2024cites this paper
• Assessing quality of blood components derived from whole blood treated with riboflavin and ultraviolet light and separated with a fully automated device.

  2022cites this paper
• Platelet-Inspired Intravenous Nanomedicine for Injury-Targeted Direct Delivery of Thrombin to Augment Hemostasis in Coagulopathies.

  2022cites this paper
• Irradiation of platelets in transfusion medicine: risk and benefit judgments

  2021cites this paper
• The Effects of Gamma Irradiation on Chemical Biomarker Recovery from Mixed Chemical/Biological Threat Exposure Specimens.

  2020cites this paper
• New strategies for the control of infectious and parasitic diseases in blood donors: the impact of pathogen inactivation methods

  2020cites this paper
• Clinical Laboratory

  2020cites this paper
• Rational design of phenothiazinium derivatives and photoantimicrobial drug discovery

  2017cites this paper
• Red blood cell hemolysis : protein biomarker discovery for product quality assessment

  2017cites this paper
• Rapid, sensitive detection of bacteria in platelet samples with Fountain Flow Cytometry

  2017cites this paper
• Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion

  2017cites this paper
• Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance

  2017cites this paper
• BLOOD BAG; PROTECTION FROM BACTERIA: REVIEWt

  2017cites this paper
• IN-SILICO ANALYSIS; ANALYSIS OF S-303 BINDING TO CD-61 OF PLATELETS

  2016cites this paper
• Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

  2016cites this paper
• Convalescent plasma: new evidence for an old therapeutic tool?

  2016cites this paper
• Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: A systematic review with regional discussion

  2016cites this paper
• Is solvent/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus document.

  2016cites this paper
• Peculiarities of studying the effects of pathogen reduction technologies on platelets

  2016cites this paper
• Human T‐lymphotropic virus and transfusion safety: does one size fit all?

  2016cites this paper
• Zika virus and the never-ending story of emerging pathogens and transfusion medicine.

  2016cites this paper
• Hepatitis E: an old infection with new implications.

  2015cites this paper
• Use of Restrictive Transfusion in Abdominal Surgery: Should Evidence-Based Medicine Replace Art of Medicine?

  2015cites this paper
• Chemical and Biological Mechanisms of Pathogen Reduction Technologies

  2014cites this paper
• Solvent/detergent plasma: pharmaceutical characteristics and clinical experience

  2014cites this paper
• p38MAPK is involved in apoptosis development in apheresis platelet concentrates after riboflavin and ultraviolet light treatment

  2014cites this paper